PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|March 27, 2023
Ingredion Announces Strategic Investments in India Expanding into High-Value Pharmaceutical Ingredients
Author(s)Alivia Leon
Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.
Advertisement
Ingredion announced on March 24, 2023 that it has completed two strategic investments in India to expand into high-value pharmaceutical applications. The company acquired Amishi Drugs & Chemicals (AD&C), a manufacturer of superdisintegrants, lubricants, and viscosifiers, and secured a majority position in Mannitab Pharma Specialties, a supplier of specialty sugars to the pharmaceutical industry.
The investments complement Ingredion’s portfolio of starch, mannitol, and dextrose product offerings, as well as expand Mannitab’s manufacturing capacity for spray-dried mannitol for direct compression. Ingredion’s portfolio also now includes binders, fillers, superdisintegrants, lubricants, gelatin replacers for softgels, viscosofiers, encapsulation materials, and parenteral-grade dextrose.
“These investments are part of our strategy to expand our specialty pharmaceutical product portfolio to better serve our customers and diversify into high-value nonfood adjacencies,” said Jim Zallie, Ingredion’s president and CEO, in a company press release.
“Ingredion looks forward to partnering with pharma and nutraceutical formulators and helping them meet regulatory challenges, progress drug development, and identify emerging trends,” added Rana Kayal, global director for pharma and nutraceuticals, in the release.
Source: Ingredion
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement